News | July 23, 2008

Global Vascular Closure Device Market to Exceed $900 Million by 2013

July 24, 2008 - According to a new Life Science Intelligence (LSI) report, “2008 Global Vascular Closure Device Markets: U.S., Europe, Rest of World,” the global market for vascular closure devices will reach nearly $1 billion in 2013.

The market for vascular closure technologies, which includes implantable devices and external compression products, has traditionally been concentrated in the U.S. and Western Europe. These technologies are used to replace or augment manual compression following diagnostic catheterizations. By reducing time to hemostasis and facilitating more rapid recovery, implantable technologies are able to reduce time in the recovery room, which contributes to better patient throughput and higher profits for catheterization labs. External compression products, which include chemically-treated patches, also simplify the process of vascular closure for the clinician and staff.

LSI expects that by 2013, implantable devices and external compression products will account for nearly half of all vascular closures in the U.S. while implantable devices will account for 56 percent of all device-based procedures. In Europe, the use of vascular closure devices in the West has been offset by broad use of manual compression in the East. Driven by favorable demographics and better access to technologies, however, vascular closure devices, especially external compression products, should experience greater adoption.

To date, the high cost of implantable vascular closure devices has limited adoption in other international markets. By 2013, however, growing catheterization volumes, better access to new healthcare technologies, an expanding middle class, and the need to increase patient throughput while meeting the standards of Western healthcare will contribute to greater adoption of these technologies. Although only limited use of implantable devices is expected, external compression products, which are significantly less expensive than implantable devices, will experience broader adoption, the study concludes.

The report covers external compression products and implantable vascular closure devices in U.S., European, and ROW markets. Established and emerging competitors are covered, including suppliers such as Abbott (ABT), AccessClosure, Cardiva Medical, CloSys, Datascope (DSCP), Marine Polymer Technologies, Medtronic (MDT), Morris Innovative Research, Possis Medical (POSS), Radi Medical Systems, Scion Cardiovascular, Therus, St. Jude Medical (STJ), Sutura (SUTU.OB), TZ Medical, and Vascular Solutions (VASC).

For more information: http://lifescienceintelligence.com, www.LSintelligence.com

Related Content

PerQseal Large Bore Closure Device Launches in Europe
News | Vascular Closure Devices | November 21, 2018
Vivasure Medical Ltd. recently announced the European launch of the PerQseal closure device for large-bore...
Vascade MVP Reduces Time to Ambulation Follow EP Procedures
News | Vascular Closure Devices | November 11, 2018
The Vascade MVP vascular closure system met its endpoints compared to manual compression in a pivotal clinical study...
Technology | Vascular Closure Devices | November 05, 2018
November 2, 2018 — Cordis, a Cardinal Health company, today announced the U.S.
Teleflex Acquires Essential Medical
News | Vascular Closure Devices | October 05, 2018
Teleflex Inc. announced the acquisition of Essential Medical Inc. Based in Exton, Pa., Essential Medical is a privately...
Cardiva Medical Announces Completion of the AMBULATE Pivotal Trial
News | Vascular Closure Devices | May 10, 2018
Cardiva Medical Inc. announced the completion of the AMBULATE pivotal trial, one of several clinical trials in the...
Cardiva Medical Announces $41 Million for AMBULATE Vascular Closure Device Trial
News | Vascular Closure Devices | February 21, 2018
Vascular closure device provider Cardiva Medical announced that the company has closed on $11 million in additional...
The bioresorbable Cordis Mynx Grip vascular closure device seals arteriotomies without use of permanent hardware.

The bioresorbable Cordis MynxGrip vascular closure device seals arteriotomies without use of permanent hardware.

Feature | Vascular Closure Devices | January 22, 2018 | Dave Fornell
While manual compression remains the gold standard for hemostasis of catheterization vascular access site arteriotomi
Vivasure Enrolls First Patient in Frontier IV Clinical Trial
News | Vascular Closure Devices | December 29, 2017
Vivasure Medical announced in October the successful enrollment of the first patient in the Frontier IV clinical study...
Overlay Init